Table 3.
Characteristics of downregulated miRNAs.
| Downregulated miRNAs | |||||
|---|---|---|---|---|---|
| miRNA | Outcome | Analysis | HR/OR and 95% CI | Source | Study |
| 1 | Recurrence | OR | 2.5 (0.7–9.1) | Estimated | Yip, 2011 [76] |
| 9 | RFS | HR | 1.3 (0.4–3.8) | Provided | Dai, 2017 [61] |
| LNM-RFS | HR | 1.4 (1.2–1.7) | Estimated | Sondermann, 2015 [77] | |
| 10b | LNM-RFS | HR | 1.2 (0.8–1.8) | Provided | Sondermann, 2015 [77] |
| 26a | DFS | HR | 2.8 (1.5–5.1) | Provided | Ren, 2017 [75] |
| OS | HR | 2.5 (1.3–4.8) | Provided | Ren, 2017 [75] | |
| OS. | N/A | N/A | N/A | Wu, 2019 [71] | |
| 31 | Recurrence | OR | 1.8 (0.5–6.7) | Estimated | Yip, 2019 [76] |
| 34b | Recurrence | OR | 5.0 (1.3–18.9) | Estimated | Zhang, 2017 [73] |
| 130-b | Recurrence | OR | 4.8 (1.3–18.1) | Estimated | Yip, 2011 [76] |
| 138 | Recurrence | OR | 2.3 (0.6–8.5) | Estimated | Yip, 2011 [76] |
| 139-5p | DFS | HR | 0.2 (0.1–0.4) | Estimated | Montero, 2019 [55] |
| Residual disease | OR | 7.0 (2.6–18.9) | Estimated | Montero, 2019 [55] | |
| 199a-3p | R-Recurrence | OR | 3.3 (1.1–9.8) | Estimated | Liu, Ch., 2017 [66] |
| 224 | Persistence | OR | 3.4 (1.6–7.0) | Estimated | Cavedon, 2017 [53] |
| Persistence | OR | 4.7 (1.4–15.3) | Estimated | Mian, 2012 [67] | |
| Progression | OR | 0.7 (0.5–0.9) | Provided | Cavedon, 2017 [53] | |
| 381 | OS | HR | 4.7 (2.6–8.5) | Provided | Huang, 2017 [62] |
| 483-5p | Recurrence | N/A | N/A | N/A | Buda, 2012 [54] |
| 486 | OS | N/A | N/A | N/A | Sun, 2019 [70] |
| 791 | OS | HR | 0.5 (0.3–0.9) | Provided | Gao, 2018 [59] |
| 1271 | OS | N/A | N/A | N/A | Chen, 2019 [57] |
| let 7a | OS | HR | 0.4 (0.2–0.9) | Provided | Liu, 2017 [65] |
Abbreviations: DFS = disease-free survival; HR = hazard ratio; LNM = lymph node metastasis; N/A = not available; OR = odds ratio; OS = overall survival; RFS = recurrence-free survival.